Mizuho initiated coverage of Tandem Diabetes (TNDM) with a Neutral rating and $20 price target The firm’s neutral stance reflects both the bullish feedback from its recent physician surveys that call for ongoing insulin pump category share gains from multiple daily injections and the expectations that more conversions will go to competition over the next two years, the analyst tells investors in a research note. Regarding competitive dynamics, Mizuho’s sample of doctors sees Tandem losing an incremental 100bps exiting 2025, reflective of higher patient preference for competing patch-pump versus tubed-pump form factors, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem announces publication of results from trial of Control-IQ+ AID technology
- Tandem Diabetes launches new Control-IQ+ technology
- Positive Outlook for Tandem Diabetes Care: Buy Rating Affirmed Amid Upcoming Trial Results
- Optimistic Buy Rating for Tandem Diabetes Care Amid Attractive Valuation and Growth Potential
- Tandem Diabetes COO buys $191K in common stock